20 May 2013
Keywords: point, bio, starts, ph, iii, trial, contrast
Article | 19 August 2002
Point Biomedical has started Phase III trials of its lead productcandidate, an ultrasound-imaging agent for assessment of myocardial
perfusion defects ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 August 2002
17 May 2013
© 2013 thepharmaletter.com